-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The BNT162b2 vaccine is an mRNA new coronary pneumonia vaccine jointly developed by Pfizer and BioNTech .
New crown pneumonia prevention researchers recently announced the research conclusions of the potential adverse events of the BNT162b2 vaccine after the mass vaccination in Israel
The researchers used data from Israel's largest health care institution to evaluate the safety of the BNT162b2 mRNA vaccine
Infect
Both the vaccinated group and the control group included 884,828 participants
Compared with the unvaccinated population, adverse events closely related to vaccination include: myocarditis (RR=3.
Differences in the risk of potential adverse events between vaccinated and non-vaccinated populations
Differences in the risk of potential adverse events between vaccination and non-vaccinated peopleBased on data from the Israeli health system, researchers believe that the BNT162b2 vaccine has nothing to do with the increased risk of most adverse events.
The researchers believe that the BNT162b2 vaccine has nothing to do with the increased risk of most adverse events, and there is clear evidence that the serious adverse events related to BNT162b2 vaccination are only myocarditis.
Original source:
Noam Barda et al.
Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting.
Leave a message here
